Orforglipron: A Diabetes Game Changer Hidden in Plain Sight

Video will be live on Monday, July 14 at 1:00 PM Central Time. 
💎 OG Members Extended Version: How does Orforglipron compare to Rybelsus? And who should consider taking it? 

▪️ Join my channel to get access to perks or simply subscribe and turn on your notifications!
▪️ Download my FREE GLP-1/GIP Medication Information Sheet and 7-Day Best Weight Journal here.
▪️ Join my Empowerment Hub and discover sustainable, evidence-based solutions to transform your health and embrace self-care without guilt.

👉 Enjoy lifetime free access to Daily Momentum and Nourish & Thrive, your go-to spaces for daily support, encouragement, and practical tips. Or, become a Core Member for just $15/month or $145/year to unlock expert coaching, exclusive resources, and a proven system that includes live Q&As and monthly toolkits, to help you create real, lasting change.
🔗 https://drdans-empowermenthub.mn.co

What the ACHIEVE-1 Trial Tells Us About the Future of Diabetes Care

I’m unpacking the latest data on Orforglipron, a once-daily oral GLP-1 receptor agonist that’s showing impressive results—lowering A1C by up to 1.5% and helping participants lose up to 15% of their body weight, without lifestyle intervention. We’ll look at the details from the ACHIEVE-1 Trial, including who was studied, how the trial was designed, and what the outcomes were across A1C, weight, cholesterol, and blood pressure.

If you’ve been navigating type 2 diabetes with diet and exercise alone, or have struggled with injections or food rules, this might be the most significant new option to know about.

For the OGs, I go deeper into who might be the best candidate for Orforglipron, who should hold off, and how it stacks up directly against Rybelsus in real-world use.

References

Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Jun 21. PMID: 40544435.

Thanks for watching and always remember: small tweaks lead to massive peaks!

Don’t forget to hit the subscribe button for more insightful content, and consider joining our YouTube Members Membership for exclusive content and early access to weekly videos. 

📺 Watch These Next:
▪️ Watch This Before Taking Mounjaro
▪️ From Ozempic to Mounjaro
▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro
▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!
▪️ Ozempic: Stomach Paralysis Update
▪️ How to Switch from Ozempic (or Wegovy) to Mounjaro
▪️ Ozempic Paralyzed My Stomach
▪️ How to Inject Mounjaro: step-by-step tutorial

🎯 Free Resources:
▪️ GLP-1/GIP Medication Info Sheet + 7-Day Food Journal
▪️ Total Daily Energy Expenditure (TDEE) Calculator – Find your optimal calorie intake


🛒 Recommended Products for Your Weight-Loss Journey:
▪️ Managing Constipation
▪️ Managing Heartburn
▪️ Protein Bars & Supplements
▪️ Activity Trackers & Scales

Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy – http://apothecarerx.ca 

 

Dr. Dan

Follow me on social media for regular updates – @TheOfficialDrDan

Subscribe to my newsletter for a heads-up on all new content.

Sharing is caring! Here’s the social, email, and even text link –
https://healthevolved.co/orforglipron2

If you need some coaching support on your weight management journey, you can book a consultation with me to see if you’d be a good fit for our program. 

Questions or comments? Please send them my way on our Contact Us page!

Share:

More Posts

Peripheral Artery Disease (PAD) & Semglutide

If walking causes burning or cramping in your legs, it could be more than just aging or being out of shape—it might be Peripheral Artery Disease (PAD). Learn how semaglutide, commonly known for weight loss and diabetes, is now showing promise in improving mobility and reducing leg pain by improving blood flow.

CagriSema vs Tirzepatide

CagriSema and Tirzepatide are two of the most talked-about names in obesity treatment—now see how they compare. Explore the latest clinical results, real-world impacts, and what sets each medication apart when it comes to weight loss and metabolic health.

Mazdutide: China’s GLP-1 Gamechanger

Mazdutide is a new GLP-1/glucagon receptor agonist from China, showing promising weight loss results in recent trials. With up to 14% reduction in a lower-BMI population, it raises key questions about how it compares to Wegovy, Zepbound, and the future of obesity treatment.

Why Nothing Tastes Good on GLP-1s

On GLP-1s like Ozempic or Wegovy, food can start to feel dull—it’s not just you. I explain why this happens and what it means for your brain, cravings, and nutrition. If meals feel joyless, there are ways to bring satisfaction and balance back.

Send Us A Message

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.

Try My New Calorie Calculator!

Calculate your daily calorie and protein targets to help you achieve your weight goals.